Standard Chemotherapy Plus Novel Drugs for Advanced Pancreatic Cancer
This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
Testing the Safety of an Immunotherapy Combination After Surgery
A new clinical trial tests the safety of a monoclonal antibody and personalized cancer vaccine combined with chemotherapy after surgery to remove pancreatic cancer.
Testing Treatment Combinations to Make Surgery More Effective
Researchers are looking at losartan and nivolumab combined with standard protocol of chemotherapy and radiation to see either drug or a combination is more effective.
Immunotherapy for Advanced Pancreatic Cancer and Other Solid Tumors
Researchers are testing the use of tumor-infiltrating lymphocytes, a type of immunotherapy, against advanced pancreatic cancer.
Immunotherapy to Enhance Standard Chemotherapy for Advanced Pancreatic Cancer
Researchers are testing an immunotherapy drug approved for other advanced cancers for effectiveness against pancreatic cancer.
Combining Immunotherapy and Targeted Therapy for Pancreatic Cancer
Researchers are combining immunotherapy and targeted therapy in a clinical trial for pancreatic cancer patients on platinum-based chemotherapy.
Immunotherapy Combination Plus Radiation for Pancreatic Cancer
Researchers are testing two monoclonal antibodies approved to treat melanoma plus radiation as a treatment for pancreatic cancer.
Finding a Safe Dose of a New Drug for Some Types of Solid Tumors
LMB-100 is a lab-created protein that targets mesothelin. It is being tested against pancreatic cancer and other solid tumors in a clinical trial.
Personalized Immunotherapy Vaccine for Pancreatic Cancer
Researchers are creating personalized vaccines to stimulate a pancreatic cancer patient's immune system after surgery and chemotherapy.
Targeting Tumor Proteins Specific to Pancreatic Cancer Cells
A clinical trial tests the safety and effectiveness of tumor-associated antigen-specific cytotoxic T lymphocytes, which target specific tumor proteins.